Daily Sepsis Research Analysis
Analyzed 18 papers and selected 3 impactful papers.
Summary
Analyzed 18 papers and selected 3 impactful articles.
Selected Articles
1. Curcumae Radix polysaccharides alleviate sepsis in rats: Isolation and characterization of an active homogeneous polysaccharide.
Using rat sepsis and endothelial injury models, the authors identified a homogeneous Curcumae Radix polysaccharide (CRP1-3) that inhibits SPHK1 signaling, protects the vascular endothelium, and reduces organ injury. Structural analysis showed CRP1-3 is a high-molecular-weight glucan with →4)-α-D-Glcp-(1→ linkages, highlighting an underappreciated class of active polysaccharides with anti-sepsis potential.
Impact: This study isolates and structurally characterizes a single active polysaccharide that mechanistically protects the endothelium via SPHK1 inhibition, addressing a central node in sepsis pathobiology. It advances natural-product-derived therapeutics with defined molecular features for sepsis.
Clinical Implications: Findings support endothelial-targeted strategies in sepsis and nominate CRP1-3 as a lead for drug development; however, translation requires pharmacokinetics, safety, and dosing studies in large animals and humans.
Key Findings
- Both polysaccharide and non-polysaccharide fractions of Curcumae Radix reduced inflammation and coagulation in an LPS+carrageenan rat sepsis model.
- Mechanistic data indicate SPHK1 pathway inhibition preserves the vascular endothelial barrier, mitigating liver and lung injury.
- Bioactivity-guided fractionation isolated a homogeneous glucan (CRP1-3, ~5082 kDa) with a →4)-α-D-Glcp-(1→ backbone that confers strong anti-inflammatory and endothelial-protective effects.
Methodological Strengths
- Bioactivity-guided isolation linking structure to function with both in vivo (rat) and in vitro (HUVEC) validation.
- Mechanistic focus on SPHK1 signaling and endothelial barrier integrity, aligned with sepsis pathophysiology.
Limitations
- Preclinical models (LPS+carrageenan and HUVEC) may not fully recapitulate human sepsis complexity.
- No pharmacokinetic, toxicity, or dose–response data for CRP1-3 to inform clinical translation.
Future Directions: Define pharmacokinetics/toxicity of CRP1-3, confirm efficacy in polymicrobial sepsis and large-animal models, and explore SPHK1-targeted combinations.
Curcumae Radix (CR), a traditional Chinese herbal medicine, has shown potential in the treatment of sepsis, yet its active substances and mechanisms of action remain unclear. In this study, CR was separated into polysaccharide and non-polysaccharide fractions. Both fractions exhibited significant anti-inflammatory and anticoagulant effects in a rat model of sepsis induced by lipopolysaccharide (LPS) and carrageenan. These effects were mediated by sphingosine kinase 1 (SPHK1) signaling pathway inhibition, which protected the vascular endothelial barrier and consequently alleviated liver and lung tissue damage and mitigated sepsis symptoms. Additionally, bioactivity-guided fractionation in an LPS-induced human umbilical vein endothelial cell (HUVEC) injury model led to the isolation of a homogeneous polysaccharide, designated as CRP1-3 with a molecular weight of 5082 kDa. A physicochemical analysis and structural characterization revealed that CRP1-3 was a glucan with a backbone composed of →4)-α-D-Glcp-(1 → linkages. CRP1-3 demonstrated significant anti-inflammatory and endothelial-protective activity. These findings established that CRP is a substantially underestimated yet critical class of small-molecule active substances contributing to the anti-sepsis efficacy of CR.
2. β-Nicotinamide mononucleotide preserves muscle strength in septic male mice.
In a cecal slurry sepsis model, muscle strength remained impaired despite recovery of mass, linked to Sirt3 downregulation and mitochondrial protein hyperacetylation. β-NMN administration during the acute phase preserved mitochondrial morphology and muscle strength without increasing muscle mass, nominating NAD+ augmentation as a strategy to prevent ICU-acquired weakness.
Impact: The study links persistent post-sepsis weakness to a defined mitochondrial deacetylation axis (Sirt3) and demonstrates rescue by β-NMN, directly informing a testable metabolic intervention for ICU-AW.
Clinical Implications: Supports early NAD+ augmentation trials (e.g., β-NMN) to prevent or attenuate ICU-acquired weakness after sepsis; biomarkers such as Sirt3 activity and mitochondrial protein acetylation may guide patient selection.
Key Findings
- Muscle strength remained impaired 14 days post-sepsis despite recovery of body weight and muscle mass, with persistent mitochondrial abnormalities.
- Sirt3 was downregulated and mitochondrial protein lysine acetylation increased; complex I subunits were detected within hyperacetylated bands.
- Acute-phase β-NMN administration preserved mitochondrial morphology and muscle strength without altering muscle mass; Sirt3 knockdown impaired respiration, partially rescued by β-NMN.
Methodological Strengths
- Integration of transcriptomics, biochemistry, and functional assays across in vitro (C2C12) and in vivo models.
- Clear mechanistic link between Sirt3 downregulation, protein hyperacetylation, and functional outcomes, with pharmacologic rescue.
Limitations
- Male mice only; sex differences and age/comorbidity effects are unknown.
- Preclinical design lacks human validation and dose-finding/safety assessments for β-NMN in sepsis.
Future Directions: Conduct phase 1/2 trials of β-NMN in sepsis survivors targeting ICU-AW prevention, including dose, safety, and biomarker-guided stratification; assess synergistic NAD+-Sirtuin pathway interventions.
Sepsis remains a leading cause of mortality and long-term disability, with survivors frequently developing intensive care unit-acquired weakness (ICU-AW) as part of post-intensive care syndrome. To identify a nutritional therapy for ICU-AW, we investigated the mechanisms underlying sepsis-induced skeletal muscle dysfunction using a cecal slurry-induced sepsis mouse model. Although body weight and skeletal muscle mass recovered 14 days after sepsis induction, muscle strength remained impaired, accompanied by persistent mitochondrial abnormalities. Transcriptomic analysis revealed that the pathways termed the 'sirtuin signaling pathway' and 'mitochondrial dysfunction' significantly enriched and Sirt3, a major mitochondrial nicotinamide adenine dinucleotide (NAD⁺)-dependent deacetylase, was downregulated. Biochemical analyses confirmed increased acetylated lysine of mitochondrial proteins in septic muscle tissue. Among these proteins, mass spectrometry detected several proteins in the acetylated band, including multiple complex I subunits. Whether these are direct SIRT3 targets remains to be determined. Knockdown of Sirt3 in C2C12 myotubes impaired mitochondrial respiration, whereas treatment with β-nicotinamide mononucleotide (β-NMN) partially rescued energy production. In vivo, acute-phase administration of β-NMN preserved mitochondrial morphology and skeletal muscle strength without altering muscle mass. These findings demonstrate that sepsis induces mitochondrial dysfunction and persistent muscle weakness associated with Sirt3 downregulation, and highlights β-NMN supplementation as a promising NAD⁺-targeted therapeutic strategy for mitigating ICU-AW.
3. Integrative multi-omics and machine learning identify mitochondrial biomarkers for pathogen-specific sepsis stratification and translational prioritization.
By integrating sepsis GWAS, blood QTLs, and independent transcriptomic cohorts, the study prioritizes mitochondrial genes with compartment-specific effects and pathogen-associated expression. A random forest model based on mitochondrial gene features achieved an AUC of 0.91 in internal cross-validation, nominating biomarker candidates for pathogen-specific sepsis stratification.
Impact: This framework links genetic regulation to clinically relevant mitochondrial signatures and demonstrates strong internal predictive performance, advancing biomarker-driven, pathogen-specific sepsis stratification.
Clinical Implications: Mitochondrial gene signatures could support early diagnostic stratification and guide targeted therapies once externally validated; prioritization informs translational assays (e.g., targeted transcriptomics/metabolomics).
Key Findings
- Integration of sepsis GWAS with blood QTL resources prioritized mitochondrial genes with convergent regulatory evidence, especially in inner membrane and matrix compartments.
- Independent transcriptomic cohorts exhibited clinically relevant dysregulation and pathogen-associated expression patterns of prioritized mitochondrial genes.
- A random forest model using mitochondrial gene features achieved an AUC of 0.91 in internal tenfold cross-validation, requiring external validation.
Methodological Strengths
- Multi-layer integration of GWAS, eQTL/pQTL, and independent transcriptomic cohorts.
- Modeling with internal cross-validation and pathogen-specific expression characterization.
Limitations
- Model performance is based on internal resampling without external cohort validation.
- Heterogeneity of public datasets and potential confounding may limit generalizability.
Future Directions: Prospective external validation with standardized sampling, integration of metabolomics and functional assays, and clinical utility assessment for pathogen-specific triage and therapy guidance.
BACKGROUND: Sepsis is a leading cause of critical illness and mortality, yet substantial heterogeneity limits risk stratification and biomarker translation. Mitochondrial dysfunction is widely implicated in sepsis, but genetically supported, multi-layer regulatory features and their clinical relevance remain incompletely characterized. METHODS: We integrated publicly available sepsis GWAS summary statistics (general sepsis: 1634 cases/454,714 controls; gram-positive sepsis: 168/456,180; gram-negative sepsis: 383/455,965) with blood-based molecular QTL resources (including GTEx v8 whole blood, n = 670) to prioritize mitochondrial genes and infer regulatory cascades. Independent whole-blood transcriptomic cohorts (the GAinS cohort, GSE65682, n = 802; GSE54514, n = 163) were used for clinical and pathogen-specific expression characterization. We developed machine learning models using mitochondrial gene features and evaluated performance by internal tenfold cross-validation. RESULTS: We identified mitochondrial genes with convergent genetic, epigenetic, and transcriptional regulatory evidence, showing stronger effects in inner membrane and matrix compartments. Transcriptomic analyses supported clinically relevant dysregulation and pathogen-associated patterns. In predictive modeling, aggregating mitochondrial gene features improved discrimination, with the best-performing random forest model achieving an AUC of 0.91 under internal cross-validation. These results require validation in independent external cohorts. CONCLUSIONS: This study provides a genetically supported, multi-omics framework linking compartment-specific mitochondrial dysregulation to sepsis heterogeneity and nominates candidate biomarkers for prioritization. The reported model performance reflects internal resampling and requires validation in independent clinical cohorts and future multi-omics profiling (including metabolomics) before translational implementation.